Use of chimeric antigen receptor modified cells to treat cancer
US9932405B2 · kind B2 · utility
9Cited by
6References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 24, 2017 |
| Grant date | Apr 3, 2018 |
| Priority date | — |
| Expiry date | Aug 24, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/515
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions and methods for compositions, methods, and kits for treating cancer using chimeric antigen receptor (CAR) modified cells. Some embodiments of the present disclosure relate to an isolated nucleic acid sequence encoding CAR. The CAR may include an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain. The antigen binding domain may bind to an antigen of a non-essential organ.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.